The effects of sildenafil citrate on urinary podocin and nephrin mRNA expression in an l-NAME model of pre-eclampsia
出版年份 2016 全文链接
标题
The effects of sildenafil citrate on urinary podocin and nephrin mRNA expression in an l-NAME model of pre-eclampsia
作者
关键词
Sildenafil citrate, Pre-eclampsia, Podocyturia, sFlt-1, PlGF
出版物
MOLECULAR AND CELLULAR BIOCHEMISTRY
Volume 427, Issue 1-2, Pages 59-67
出版商
Springer Nature
发表日期
2016-12-19
DOI
10.1007/s11010-016-2897-5
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Use of serum and urinary soluble sFlt-1 and PLGF in the diagnosis of preeclampsia
- (2016) Ping Tang et al. HYPERTENSION IN PREGNANCY
- Oral administration of veratric acid, a constituent of vegetables and fruits, prevents cardiovascular remodelling in hypertensive rats: a functional evaluation
- (2015) Murugesan Saravanakumar et al. BRITISH JOURNAL OF NUTRITION
- Effect of Sildenafil on Pre-Eclampsia-Like Mouse Model Induced By L-Name
- (2015) C Motta et al. REPRODUCTION IN DOMESTIC ANIMALS
- The optimization of a chronic nitric oxide synthase (NOS) inhibition model of pre-eclampsia by evaluating physiological changes
- (2014) Sooraj Baijnath et al. European Journal of Obstetrics & Gynecology and Reproductive Biology
- Sildenafil Citrate for Prophylaxis of Nephropathy in an Animal Model of Contrast-Induced Acute Kidney Injury
- (2014) D. Adam Lauver et al. PLoS One
- Structural characterization and mutational assessment of podocin — A novel drug target to nephrotic syndrome — An in silico approach
- (2014) Asra Tabassum et al. Interdisciplinary Sciences-Computational Life Sciences
- Dysregulation of Hydrogen Sulfide Producing Enzyme Cystathionine γ-lyase Contributes to Maternal Hypertension and Placental Abnormalities in Preeclampsia
- (2013) Keqing Wang et al. CIRCULATION
- The role of angiogenic, anti-angiogenic and vasoactive factors in pre-eclamptic African women : early- versus late-onset pre-eclampsia
- (2012) Lucinda Govender et al. Cardiovascular Journal of Africa
- Phosphodiesterase-5 and Retargeting of Subcellular cGMP Signaling During Pathological Hypertrophy
- (2012) Rakesh C. Kukreja CIRCULATION
- Cyclic Guanosine Monophosphate Signaling and Phosphodiesterase-5 Inhibitors in Cardioprotection
- (2012) Rakesh C. Kukreja et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Mass spectrometry as a novel method for detection of podocyturia in pre-eclampsia
- (2012) Vesna D. Garovic et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- An unexpected tail of VEGF and PlGF in pre-eclampsia
- (2011) David O. Bates BIOCHEMICAL SOCIETY TRANSACTIONS
- Mechanisms and Potential Therapies for Preeclampsia
- (2011) Eric M. George et al. CURRENT HYPERTENSION REPORTS
- Sildenafil citrate decreases sFlt-1 and sEng in pregnant l-NAME treated Sprague–Dawley rats
- (2011) S.V. Ramesar et al. European Journal of Obstetrics & Gynecology and Reproductive Biology
- Cardiac Uses of Phosphodiesterase-5 Inhibitors
- (2011) Bryan G. Schwartz et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Sildenafil citrate improves fetal outcomes in pregnant, l-NAME treated, Sprague–Dawley rats
- (2010) S.V. Ramesar et al. European Journal of Obstetrics & Gynecology and Reproductive Biology
- Pre-eclampsia
- (2010) Eric AP Steegers et al. LANCET
- Phosphodiesterase-5 Inhibitor, Tadalafil, Protects Against Myocardial Ischemia/Reperfusion Through Protein-Kinase G-Dependent Generation of Hydrogen Sulfide
- (2009) F. N. Salloum et al. CIRCULATION
- Urine Podocyte mRNAs Mark Progression of Renal Disease
- (2009) Y. Sato et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- The Global Impact of Pre-eclampsia and Eclampsia
- (2009) Lelia Duley SEMINARS IN PERINATOLOGY
- Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia
- (2008) Antonio De Vivo et al. ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More